Development and validation of a novel transdermal patch formulation for sustained release of a targeted anti-inflammatory drug.

Project Abstract

The study reports the development and validation of an innovative transdermal patch designed for sustained delivery of a targeted anti-inflammatory drug, aiming to improve patient adherence, reduce peak-trough related side effects, and achieve steady therapeutic plasma concentrations over an extended period. The patch leverages a multilayered matrix system incorporating a rate-controlling backing layer, a drug-in-adhesive reservoir, and a biocompatible permeation enhancer to optimize transdermal flux while minimizing local skin irritation. An iterative formulation development process was employed, beginning with solubility screening, compatibility studies with excipients, and assessment of the drug’s physicochemical properties to inform patch architecture. In vitro release studies were conducted using Franz diffusion cells with synthetic membranes to establish initial release kinetics, followed by ex vivo skin permeation experiments on human cadaver or porcine skin to approximate real-world absorption and to identify a formulation that achieves a target flux corresponding to therapeutic plasma levels. In addition, a design of experiments approach was used to optimize key parameters, including drug loading, adhesive matrix viscosity, enhancer concentration, and patch surface area, ensuring robust performance across batch variations. Pharmacokinetic modeling was performed to translate in vitro and ex vivo data into predicted in vivo profiles, with emphasis on achieving zero-order-like release over 72 hours and minimizing lag time. Thermal and mechanical stability assessments under accelerated conditions were conducted to evaluate shelf-life viability, while chemical stability studies confirmed drug integrity and absence of degradation products under the chosen formulation and storage conditions. Biocompatibility was evaluated through in vitro cytotoxicity assays and dermal irritation tests in appropriate animal models, ensuring safety for human use. The patch demonstrated controlled, predictive release with a steady-state flux within the therapeutic window, reduced Cmax relative to oral dosing, and a favorable skin tolerability profile. The study also examined potential systemic exposure risks, evaluated the influence of skin variability on delivery efficiency, and conducted sensitivity analyses to identify critical factors affecting performance. Comparative analyses against conventional topical gels and oral administration highlighted superior adherence, reduced dosing frequency, and improved patient quality of life metrics in simulated chronic inflammatory conditions. The final formulation exhibited scalable manufacturing feasibility, reproducible patch integrity during wear-time, and compatibility with standard packaging. The research integrates rheological characterization, diffusion kinetics, and pharmacokinetic modeling to provide a comprehensive framework for translating transdermal anti-inflammatory therapy from bench to bedside, offering a viable alternative for patients with chronic inflammatory diseases who require consistent, convenient, and tolerable drug delivery. Limitations include translational gaps between ex vivo findings and in vivo human responses, potential interindividual skin differences, and the need for long-term clinical validation to confirm sustained efficacy and safety across diverse populations.

Project Overview

What This Project Is About

---

A straightforward exploration of a skin-friendly patch that releases a chosen anti-inflammatory drug slowly over time. The project looks at how to design, test, and verify a patch so the medicine stays effective for longer without frequent reapplication.

---

---

The Problem It Addresses

---

Many anti-inflammatory medicines work well, but taking pills can cause stomach upset and other side effects. A transdermal patch can deliver medicine through the skin, reducing stomach issues and improving adherence, but it must control how fast and how much drug is released. This project investigates how to achieve reliable, sustained release from a patch.

---

---

Objectives of the Project

---

1. Identify a suitable anti-inflammatory drug for transdermal delivery.
2. Formulate a patch that provides steady drug release over a chosen period.
3. Test the patch for skin compatibility and safety in basic models.
4. Measure how much drug is released over time in lab tests.
5. Assess the patch’s stability under different conditions.

---

---

What You Will Do Step by Step

---

1. Review simple literature on transdermal delivery and patch design.
2. Choose materials (carrier support, adhesive, and drug) suitable for skin contact.
3. Prepare prototype patches and perform preliminary release tests.
4. Conduct diffusion studies to map release rate over time.
5. Evaluate skin safety using basic in vitro tests or surrogate models.
6. Analyze data to confirm a consistent release profile.
7. Check patch stability under light, heat, and humidity.
8. Summarize findings and discuss potential improvements.

---

---

Expected Outcome

The project should yield a patch that delivers a defined amount of drug steadily over the target period, with data supporting safety, stability, and release consistency. This could inform further development toward clinical testing and real-world use.